Literature DB >> 16700890

Antisense oligonucleotides: from design to therapeutic application.

Jasmine H P Chan1, Shuhui Lim, W S Fred Wong.   

Abstract

1. An antisense oligonucleotide (ASO) is a short strand of deoxyribonucleotide analogue that hybridizes with the complementary mRNA in a sequence-specific manner via Watson-Crick base pairing. Formation of the ASO-mRNA heteroduplex either triggers RNase H activity, leading to mRNA degradation, induces translational arrest by steric hindrance of ribosomal activity, interferes with mRNA maturation by inhibiting splicing or destabilizes pre-mRNA in the nucleus, resulting in downregulation of target protein expression. 2. The ASO is not only a useful experimental tool in protein target identification and validation, but also a highly selective therapeutic strategy for diseases with dysregulated protein expression. 3. In the present review, we discuss various theoretical approaches to rational design of ASO, chemical modifications of ASO, ASO delivery systems and ASO-related toxicology. Finally, we survey ASO drugs in various current clinical studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700890     DOI: 10.1111/j.1440-1681.2006.04403.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  97 in total

1.  Computational prediction of efficient splice sites for trans-splicing ribozymes.

Authors:  Dario Meluzzi; Karen E Olson; Gregory F Dolan; Gaurav Arya; Ulrich F Müller
Journal:  RNA       Date:  2012-01-24       Impact factor: 4.942

Review 2.  Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

Authors:  Andrew B Hill; Mingfu Chen; Chih-Kuang Chen; Blaine A Pfeifer; Charles H Jones
Journal:  Trends Biotechnol       Date:  2015-12-23       Impact factor: 19.536

3.  Stepwise synthesis of RNA conjugates carrying peptide sequences for RNA interference studies.

Authors:  Anna Aviñó; Sandra M Ocampo; Clara Caminal; José Carlos Perales; Ramon Eritja
Journal:  Mol Divers       Date:  2009-02-03       Impact factor: 2.943

Review 4.  Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines.

Authors:  John D Johnston; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

5.  Formation of S-Cl phosphorothioate adduct radicals in dsDNA S-oligomers: hole transfer to guanine vs disulfide anion radical formation.

Authors:  Amitava Adhikary; Anil Kumar; Brian J Palmer; Andrew D Todd; Michael D Sevilla
Journal:  J Am Chem Soc       Date:  2013-08-14       Impact factor: 15.419

Review 6.  Modulation of polycystic kidney disease by non-coding RNAs.

Authors:  Harini Ramalingam; Matanel Yheskel; Vishal Patel
Journal:  Cell Signal       Date:  2020-01-23       Impact factor: 4.315

7.  Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.

Authors:  Eugene J Wyatt; Alexis R Demonbreun; Ellis Y Kim; Megan J Puckelwartz; Andy H Vo; Lisa M Dellefave-Castillo; Quan Q Gao; Mariz Vainzof; Rita C M Pavanello; Mayana Zatz; Elizabeth M McNally
Journal:  JCI Insight       Date:  2018-05-03

8.  RNA therapeutics: RNAi and antisense mechanisms and clinical applications.

Authors:  Jessica Chery
Journal:  Postdoc J       Date:  2016-07

9.  STAT3 inhibition of gluconeogenesis is downregulated by SirT1.

Authors:  Yongzhan Nie; Derek M Erion; Zhenglong Yuan; Marcelo Dietrich; Gerald I Shulman; Tamas L Horvath; Qian Gao
Journal:  Nat Cell Biol       Date:  2009-03-22       Impact factor: 28.824

10.  Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Authors:  Annemieke Aartsma-Rus; Laura van Vliet; Marscha Hirschi; Anneke A M Janson; Hans Heemskerk; Christa L de Winter; Sjef de Kimpe; Judith C T van Deutekom; Peter A C 't Hoen; Gert-Jan B van Ommen
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.